The bar chart indicated that augmented expression of AFAP1L1 significantly amplified the risk of LGG, STAD, BRCA, and LUSC, and concomitantly diminished the risk of SARC and KIRC (Fig. 2A). Here, AFAP1L1 is linked to gastric adenocarcinoma.